Shionogi & Co. has signed a basic agreement with the government to supply an oral COVID-19 treatment it is now developing, the firm said Friday.
The government is considering buying a million doses of the drug, pending regulatory approval, the company added in a statement.
Unable to view this article?
This could be due to a conflict with your ad-blocking or security software.
Please add japantimes.co.jp and piano.io to your list of allowed sites.
We humbly apologize for the inconvenience.